Shire Plc Ads


The 3 Biotech Stocks You Need in Your Portfolio

The numbers are staggering. Over the next six years, the biotech market is expected to add an additional $593 billion in value – a 419% increase over the size of today's biotech market.

Growth like this is why Wall Street is rushing hand over foot to buy the most lucrative biotech stocks available. With thousands of biotech stocks on the market, identifying the best biotech stocks to buy is incredibly difficult.

However, using the Money Morning Stock VQScore™ system, we've identified 3 biotech stocks that are on track to deliver triple-digit returns.


The 3 Best Biotech Stocks to Buy in June 2018

By 2025, the biotech industry will be worth will be $727 billion – a 120% increase over its total value in 2015.

To help you take advantage of the tremendous gains in biotech stocks, we're bringing you the three best biotech stocks to buy this month.

You see, Wall Street has put some of the best biotech stocks "on sale" due to fears over development delays, Washington's pushback against high drug prices, and a lack of consumer demand.


The 3 Best Biotech Stocks to Buy Today

Since hitting a high in late January, the iShares Nasdaq Biotechnology ETF has slumped more than 11%. But that doesn't mean investors should stop looking for the best biotech stocks to buy today.

You see, the slump in biotech stocks has little to do with their true worth.

In fact, some of the best biotech stocks are currently trading well below their fundamental value, according to their earnings and assets.

Here are the three best biotech stocks to buy now, while they're still on sale...


Double Your Money with the Best Biotech Stock to Buy in 2018

Biotech stocks were among 2017's best performers, until news broke in October that congressional Republicans ditched efforts to repeal and replace Obamacare.

While the rest of the market was still soaring, the Wall Street herd simply turned its attention elsewhere – but that was a big mistake.

In fact, the best biotech stock we're bringing readers today could bring gains over 110% in 2018 alone...


My Top Biotech Play for 2018 Could Make You 110.5% in 12 Months, If You Act Now

Between Oct. 5 and Nov. 11, one of the bellwether biotech exchange-traded funds fell 10.5%.

That's a correction, as defined by most market watchers.

And most investors – and their "enablers" on Wall Street – have shied away from biotech shares since. They're jittery.

In fact, I saw one august financial publication – the highly respected Investor's Business Daily – warn folks away from biotech in 2018 due to "median tenure of chief executives at large-cap biotech companies."

That's not just a stretch. It's a load of malarkey.

Here's the thing: If you want to double your money in 2018, you absolutely must invest in biotech.

That temporary dip in the iShares Nasdaq Biotechnology Index Fund ETF came after congressional Republicans ditched efforts to repeal and replace Obamacare. If there's one thing Wall Street hates, it's uncertainty.

As you might expect, Wall Street's panic led it to ignore some shares that have very bright futures – and are now trading at huge discounts.

So I've crunched the numbers – and done the research – and have identified three beaten-down biotech leaders that are poised to make huge comebacks throughout 2018.

I think you should put all three of these 2018 biotech comeback stocks on your "buy" list.

Especially the one that I believe will soar 110.5% in just 12 months...


Three Biotech Bargains to Buy Right Now

Back in October, I did something crazy.

That's when I told the paid-up members of my Radical Technology Profits trading service to buy a small-cap biotech stock.

Here's why that move was a bit nuts.

At the time, it looked like Hillary Clinton would soon enter in the White House and clamp down on drug prices – and so the biopharmaceutical sector was deeply out of favor.

Turns out, however, our crazy bet paid off.

Despite his campaign rhetoric, President Donald Trump has pulled back from his own fiery rhetoric about drug-price caps.

That helped pushed biotech and drug stocks into a big uptrend.

And my paid-up members made peak gains of 116% – in just over eight months.

Today, things have changed – and investing in biopharma stocks is generally seen as a smart move. However, that means a lot of these shares have been bid up, and your best move is to buy big winners at deep discounts.

But to do that, you have to know how to find those deals.

I do.

Today I'll show you how you can, too.

And I'll reveal the three best biotech bargains out there right now.

All three have triple-digit gains potential...


The Five Most Outrageous Drug Price Increases of 2016

Some of the most outrageous drug price increases of 2016 have placed huge burdens on patients and caregivers alike. According to an Oct. 11 report funded by the American Hospital Association (AHA), total net spending on prescription drugs by hospitals this year is up to $309.5 billion, making prescription drugs the fastest-growing segment of the […]

Here's our list of the most outrageous drug price increases of 2016...